We are live on ! Find out more

Labcorp

LH

Market cap $27.3B

336.54 USD

+0.82

0.24%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

336.54

0.00

0%

1 day

0.24%

5 days

1.16%

1 month

11.74%

3 months

30.32%

6 months

16.4%

Year to date

33.73%

1 year

20.49%

5 years

30.35%

10 years

184.41%

About: Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

Employees: 71,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.7%

Neutral 43.9%

Negative 2.4%

Zacks Investment Research

Should You Continue to Hold Labcorp Stock in Your Portfolio?

LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.

Should You Continue to Hold Labcorp Stock in Your Portfolio?

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings

Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease Intended for individuals 55 and older with signs, symptoms or complaints of cognitive decline BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA).

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings

Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health

Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.

Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health

Labcorp to Host Investor Day on September 10, 2026

BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m.

Labcorp to Host Investor Day on September 10, 2026

The Motley Fool

Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million

The CEO liquidated 4,669 shares at a price of $320.37 per share, totaling ~$1.5 million on August 11, 2026. The transaction resulted in a 4% reduction of the executive's total equity holdings in the company.

Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million

Zacks Investment Research

Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?

LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.

Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?

Zacks Investment Research

Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Zacks Investment Research

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

Zacks Investment Research

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

See News Rankings

Price charts implemented using Lightweight Charts™